Navigation Links
Irvine Scientific and Selexis to Announce Results of Successful Collaboration
Date:10/12/2009

GENEVA, and SANTA ANA, Calif., Oct. 12 /PRNewswire/ -- Selexis SA ("Selexis") and Irvine Scientific Inc. ("Irvine") announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines. Irvine and Selexis will jointly present the results on Tuesday, October 13, 2009 at 11:45 AM at the BioProcess International Conference 2009 being held in Raleigh, North Carolina. Results of the program demonstrate the ability to produce gram quantities of therapeutic antibodies in 16 weeks using a CHO platform designed specifically for large scale cGMP manufacturing.

"By combining the world class media development capabilities found at Irvine Scientific with the speed and performance of the Selexis SURE Cell Line Development(TM) program a very powerful CHO based production platform has been developed," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "This platform can be implemented for the production large qualities of antibody or recombinant protein useful for preclinical and clinical development purposes, which is beneficial to both our licensees and service clients."

"Our scientists have been able to quickly develop and apply an advanced media program to support the speed and performance of the Selexis system in achieving gram per liter productivities in matter of weeks," said Makoto Shintani, Chief Executive Officer. "It is clear that this program can provide significant benefits to biotech companies in need of large quantities of antibodies or proteins quickly."

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About Irvine Scientific:

Irvine Scientific, a subsidiary of Japan Energy Corporation, is a worldwide leader in the design, manufacture and distribution of medical devices including Industrial Cell Culture, Cytogenetic, and Assisted Reproductive Technology (ART) products. Irvine Scientific is a large scale producer of advanced and quality cell culture media for the industrial bioprocess and diagnostic markets. The company has extensive experience in the design of culture media leading to significant improvement in biopharmaceutical production yield. The company also manufactures media for medical and stem cell applications.

Irvine Scientific's worldwide distribution channels deliver products to large scale biopharmaceutical industry and to the research and laboratory communities.

    For more information contact:

    Irvine Scientific
    Phone: +949-261-7800
    Email tmrequest@irvinesci.com

    Selexis
    Phone: +41 (0)22 308 93 60
    Email: SURE@selexis.com

SOURCE Irvine Scientific Inc.


'/>"/>
SOURCE Irvine Scientific Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division
2. Irvine Scientific Announced Today a New Distribution Partnership With Prodimed
3. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
4. Irvine Scientific Launches IS CHO-CD XP(TM)
5. Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
6. Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy
7. BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Nanogea Announces New Scientific Advisory Board Members
10. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
11. Global Public Health the Focus of Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):